Clinical Significance of Chromodomain Helicase/ATPase DNA Binding Protein 1-like and Human MutL Homolog 1 Gene Expression in Cholangiocarcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Aug 22

PMID 30127888

Citations 2

Authors

Jingwen Hua

Shiniao Li

Changwen Huang

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma is a highly malignant form of gastrointestinal cancer with an unfavorable prognosis. The novel oncogene chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) has been confirmed to serve a vital role in numerous types of cancer, including liver cancer. Mismatch repair (MMR) is a common DNA repair process that contributes to the preservation of the integrity and stability of genetic substances. Human mutL homolog 1 gene (hMLH1) is an important MMR protein family member. The present study aimed to evaluate the pathological and clinical features of cholangiocarcinoma, and to investigate the clinical significance of CHD1L and hMLH1 expression in cholangiocarcinoma. A total of 108 samples from cholangiocarcinoma tumor tissues and 60 samples from normal bile duct tissue were obtained from patients admitted to The Second Affiliated Hospital of Nanchang University between May 2005 and May 2014. All cholangiocarcinoma cases were pathologically confirmed. The expression of CHD1L and hMLH1 was examined by immunohistochemistry analysis. The expression of CHD1L in cholangiocarcinoma (94.44%) was significantly higher than in normal bile duct tissues (40.00%). CHD1L expression was associated with gallstone history, serum carbohydrate antigen 19-9 (CA19-9) level and Tumor-Node-Metastasis (TNM) stage (P<0.05). hMLH1 expression in cholangiocarcinoma (77.78%) was significantly lower than in normal bile duct tissues (96.67%), and was associated with gender, age, serum CA19-9 level, the presence of hepatitis B virus surface antigen, TNM stage and tumor diameter (P<0.05). Kaplan-Meier survival curve analysis indicated that the 3-year accumulative survival rates for CHD1L-positive and -negative patients differed significantly (P<0.05; 17.90 and 83.33%, respectively). There was no statistically significant difference (P>0.05) between the 3-year accumulate survival rates for hMLH1-positive and -negative patients (38.90 and 33.30%, respectively). High CHD1L expression and low hMLH1 expression levels were observed in patients with cholangiocarcinoma, and their abnormal expression patterns were associated with the progression of malignancy and an unfavorable disease prognosis. Therefore, CHD1L and hMLH1 may be potential prognostic biomarkers for cholangiocarcinoma.

Citing Articles

Diversity roles of CHD1L in normal cell function and tumorigenesis.

Xiong X, Lai X, Li A, Liu Z, Ma N Biomark Res. 2021; 9(1):16.

PMID: 33663617 PMC: 7934534. DOI: 10.1186/s40364-021-00269-w.

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.

Marrugal A, Ferrer I, Pastor M, Ojeda L, Quintanal-Villalonga A, Carnero A Cells. 2019; 8(8).

PMID: 31370342 PMC: 6721529. DOI: 10.3390/cells8080806.

References

Ghouri Y, Mian I, Blechacz B . Cancer review: Cholangiocarcinoma. J Carcinog. 2015; 14:1. PMC: 4360553. DOI: 10.4103/1477-3163.151940. View

He L, Ma N, Chen J, Li B, Guan X, Liu M . Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget. 2015; 6(31):31181-90. PMC: 4741596. DOI: 10.18632/oncotarget.5070. View

Nam T, Lee J, Cho S, Chung I, Ahn S, Song J . Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett. 2007; 260(1-2):109-17. DOI: 10.1016/j.canlet.2007.10.026. View

Yan S, Sorrell M, Berman Z . Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress. Cell Mol Life Sci. 2014; 71(20):3951-67. PMC: 4176976. DOI: 10.1007/s00018-014-1666-4. View

Zhang R, Qin W, Xu G, Zeng F, Li C . A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer. Colorectal Dis. 2011; 14(3):e80-9. DOI: 10.1111/j.1463-1318.2011.02858.x. View

Su Z, Zhao J, Xian G, Geng W, Rong Z, Wu Y . CHD1L is a novel independent prognostic factor for gastric cancer. Clin Transl Oncol. 2013; 16(8):702-7. DOI: 10.1007/s12094-013-1136-8. View

Chen L, Chan T, Yuan Y, Hu L, Huang J, Ma S . CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 2010; 120(4):1178-91. PMC: 2846051. DOI: 10.1172/JCI40665. View

Wu J, Zong Y, Fei X, Chen X, Huang O, He J . Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer. PLoS One. 2014; 9(8):e98673. PMC: 4143172. DOI: 10.1371/journal.pone.0098673. View

Giedl J, Schneckenpointner R, Filbeck T, Ruemmele P, Hofstaedter F, Burger M . Low frequency of HNPCC-associated microsatellite instability and aberrant MMR protein expression in early-onset bladder cancer. Am J Clin Pathol. 2014; 142(5):634-9. DOI: 10.1309/AJCPVTCJ4VU5HKVZ. View

10.

Tyson G, El-Serag H . Risk factors for cholangiocarcinoma. Hepatology. 2011; 54(1):173-84. PMC: 3125451. DOI: 10.1002/hep.24351. View

11.

Ji X, Li J, Zhu L, Cai J, Zhang J, Qu Y . CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. J Surg Res. 2013; 185(1):84-91. DOI: 10.1016/j.jss.2013.05.008. View

12.

Plevova P, Krepelova A, Papezova M, Sedlakova E, curik R, Foretova L . Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer. Neoplasma. 2004; 51(4):275-84. View

13.

Schweitzer N, Vogel A . Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol. 2015; 29(2):345-53. DOI: 10.1016/j.bpg.2015.01.002. View

14.

Kamarajah S, Burns W, Frankel T, Cho C, Nathan H . Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol. 2017; 24(7):2023-2030. DOI: 10.1245/s10434-017-5810-x. View

15.

Kuan J, Wu C, Sun C, Chu C, Lin F, Hsu C . DNA methylation combinations in adjacent normal colon tissue predict cancer recurrence: evidence from a clinical cohort study. PLoS One. 2015; 10(3):e0123396. PMC: 4376718. DOI: 10.1371/journal.pone.0123396. View

16.

Vageli D, Daniil Z, Dahabreh J, Karagianni E, Vamvakopoulou D, Ioannou M . Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer. 2008; 64(3):282-8. DOI: 10.1016/j.lungcan.2008.09.018. View

17.

Gu M, Bae Y, Kim A, Hong S, Yu E, Kim J . Expression of hMLH1, hMSH2 and hMSH6 in small intestinal carcinomas. Hepatogastroenterology. 2012; 59(119):2228-32. DOI: 10.5754/hge11601. View

18.

He W, Zhou J, Cai M, Xiao X, Liao Y, Kung H . CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 2012; 12:437. PMC: 3551745. DOI: 10.1186/1471-2407-12-437. View

19.

Tian F, Xu F, Zhang Z, Ge J, Wei Z, Xu X . Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumour Biol. 2013; 34(6):3687-90. DOI: 10.1007/s13277-013-0951-4. View

20.

Park J, Chang H, Park S, Kim B, Kim D, Baek J . Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers. Ann Surg Oncol. 2010; 17(11):2839-46. DOI: 10.1245/s10434-010-1135-8. View